

## Product Datasheet

# CEP-37440

Catalog No. **BP-02495** · CAS **1391712-60-9** · Form **free base** · Physical state **other** · Color **White to yellow** · Version **1.0** · Revision **2026-09-10**


**FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.**

|                                                        |                                |
|--------------------------------------------------------|--------------------------------|
| Target<br><b>Anaplastic lymphoma kinase (ALK); FAK</b> | Research area<br><b>Cancer</b> |
|--------------------------------------------------------|--------------------------------|

Molecular formula **C<sub>30</sub>H<sub>38</sub>ClN<sub>7</sub>O<sub>3</sub>**

Molecular weight **580.1210**

### STRUCTURE



## DESCRIPTION

CEP-37440 is a potent, orally active dual FAK/ALK inhibitor with IC<sub>50</sub> values of 2.3 nM and 3.5 nM for FAK and ALK, respectively. CEP-37440 decreases the cell proliferation by blocking the autophosphorylation kinase activity of FAK1 (Tyr 397) .

## BIOLOGICAL ACTIVITY

Preparation of fused bicyclic 2,4-diaminopyrimidine derivatives as a dual ALK and FAK inhibitor.

## SOLUBILITY

Soluble in DMSO

**In vitro** DMSO : 100 mg/mL

## REFERENCES

- [1].Salem I, et, al. The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells. Breast Cancer Res. 2016 Mar 24;18(1):37.
- [2].Ott GR, et, al. Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK). J Med Chem. 2016 Aug 25;59(16):7478-96.